EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner, Marc Braunstein, Ludek Pour, Josep M Martí, Supratik Basu, Yael C Cohen, Morio Matsumoto, Kenshi Suzuki und 19 weitere

Nature Medicine · 2025-04 · 31 (4) · 1195-1202

DOI: 10.1038/s41591-024-03485-7 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Nature Medicine, online erschienen am 05.02.2025. Verfasst von Saad Z Usmani und 30 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org. Hauptthemen laut MEDLINE: Multiple Myeloma, Lenalidomide, Dexamethasone, Bortezomib. Die Arbeit wurde bisher 166-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, This study was sponsored by Janssen Research & Development, LLC..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineligible NDMM, triplet therapy with either daratumumab plus lenalidomide and dexamethasone (D-Rd) or bortezomib, lenalidomide and dexamethasone (VRd) is the current standard of care. This phase 3 trial evaluated subcutaneous daratumumab plus VRd (D-VRd) in patients with transplant-ineligible NDMM or for whom transplant was not planned as the initial therapy (transplant deferred). Some 395 patients with transplant-ineligible or transplant-deferred NDMM were randomly assigned to eight cycles of D-VRd or VRd followed by D-Rd or Rd until progression. The primary endpoint was overall minimal residual disease (MRD)-negativity rate at 10 − 5 by next-generation sequencing. Major secondary endpoints included complete response (CR) or better (≥CR) rate, progression-free survival and sustained MRD-negativity rate at 10 − 5 . At a median follow-up of 58.7 months, the MRD-negativity rate was 60.9% with D-VRd versus 39.4% with VRd (odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55; P < 0.0001). Rates of ≥CR (81.2% versus 61.6%; P < 0.0001) and sustained MRD negativity (≥12 months; 48.7% versus 26.3%; P < 0.0001) were significantly higher with D-VRd versus VRd. Risk of progression or death was 43% lower for D-VRd versus VRd (hazard ratio, 0.57; 95% CI, 0.41–0.79; P = 0.0005). Adverse events were consistent with the known safety profiles for daratumumab and VRd. Combining daratumumab with VRd produced deeper and more durable MRD responses versus VRd alone. The present study supports D-VRd quadruplet therapy as a new standard of care for transplant-ineligible or transplant-deferred NDMM. ClinicalTrials.gov registration: NCT03652064 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaLenalidomideDexamethasoneBortezomibAntineoplastic Combined Chemotherapy ProtocolsAntibodies, MonoclonalHumansMaleFemaleAgedMiddle AgedNeoplasm, ResidualAdultProgression-Free SurvivalAged, 80 and over

Substanzen

daratumumabLenalidomideDexamethasoneBortezomibAntibodies, Monoclonal

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org.
  • University of Lille, CHU de Lille, Service des Maladies du Sang, Lille, France.
  • Clínica Médica São Germano, São Paulo, Brazil.
  • Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
  • Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
  • BC Cancer-Vancouver Centre, University of British Columbia, Vancouver, British Columbia, Canada.

Förderung

  • NCI NIH HHS
  • This study was sponsored by Janssen Research & Development, LLC.

Zitieren

APA

Usmani, S. Z., Facon, T., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M., Pour, L., Martí, J. M., Basu, S., Cohen, Y. C., Matsumoto, M., Suzuki, K., Hulin, C., Grosicki, S., Legiec, W., Beksac, M., Maiolino, A., Takamatsu, H., Perrot, A., …, & Zweegman, S. (2025). Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nature Medicine, 31(4), 1195-1202. https://doi.org/10.1038/s41591-024-03485-7

Vancouver

Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nature Medicine. 2025;31(4):1195-1202. doi:10.1038/s41591-024-03485-7

BibTeX
@article{Usmani2025,
  author = {Usmani, Saad Z and Facon, Thierry and Hungria, Vania and Bahlis, Nizar J and Venner, Christopher P and Braunstein, Marc and Pour, Ludek and Martí, Josep M and Basu, Supratik and Cohen, Yael C and Matsumoto, Morio and Suzuki, Kenshi and Hulin, Cyrille and Grosicki, Sebastian and Legiec, Wojciech and Beksac, Meral and Maiolino, Angelo and Takamatsu, Hiroyuki and Perrot, Aurore and Turgut, Mehmet and Ahmadi, Tahamtan and Liu, Weiping and Wang, Jianping and Chastain, Katherine and Vermeulen, Jessica and Krevvata, Maria and Lopez-Masi, Lorena and Carey, Jodi and Rowe, Melissa and Carson, Robin and Zweegman, Sonja},
  title = {Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial},
  journal = {Nature Medicine},
  year = {2025},
  volume = {31},
  number = {4},
  pages = {1195--1202},
  doi = {10.1038/s41591-024-03485-7}
}
Kostenlos starten →